MedTrace Logo

Dextromethorphan, Amantadine and Glucose Homeostasis in Diabetes Subjects

NCT01441986 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2012-07-12

No results posted yet for this study

Summary

The purpose of this trial is to demonstrate that dextromethorphan (DXM) and amantadine compared to placebo exert blood glucose (BG) lowering effects following an oral glucose tolerance test (OGTT) in male subjects with T2DM.

Conditions

Interventions

DRUG

Dextromethorphan hydrobromide

Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.

DRUG

Amantadine

Amantadine hydrochloride 100 mg; tablets; single, oral dose.

DRUG

Pacebo 1 (placebo for Amantadine)

Talets for oral use; single dose.

DRUG

Placebo 2 (fo Dextromethorphan)

Capsles for oral administration; single dose.

Sponsors & Collaborators

  • Heinrich-Heine University, Duesseldorf

    collaborator OTHER

  • Profil Institut für Stoffwechselforschung GmbH

    lead INDUSTRY

Principal Investigators

  • Alin O Stirban, MD · Profil Institute for Metabolic Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
45 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01441986 on ClinicalTrials.gov